Vanguard Eldercare Rebrands as GuideStar Eldercare

Vanguard Eldercare Rebrands as GuideStar Eldercare




Vanguard Eldercare Rebrands as GuideStar Eldercare

CROWN POINT, Ind.–(BUSINESS WIRE)–Vanguard Eldercare announced today that it has changed its name to GuideStar Eldercare. Building upon two decades of regionally recognized leadership in the field of neuro-behavioral healthcare, the rebrand positions the company for national expansion.

Beyond the business considerations of expanding into states where the Vanguard name is not able to be trademark protected, the new GuideStar brand reflects the positive impact our services and clinicians have on the facility-partners and shared residents we serve,” said Dr. Steven L. Posar, M.D., founder and Chief Executive Officer for Vanguard/GuideStar Eldercare.

Since 2003, Vanguard Eldercare has provided integrated neurological, psychiatric, medical, geriatric, and psychological health care to patients with neurological and/or behavioral illness in long-term care and post-acute settings throughout the Midwest. Under the new GuideStar Eldercare brand, the neuro-behavioral health company will continue to enhance its services and expand upon the clinical and compliance protocols shown to positively affect 50 percent of the Centers for Medicare & Medicaid Services (CMS) long-stay quality measures that help determine a skilled nursing facility’s star rating.

GuideStar Eldercare’s innovative neuro-behavioral care model centers on practicing accurate diagnostic and pharmacological protocols, tailored psychological interventions, understanding and commitment to CMS regulatory compliance, and advancing independent living, assisted living, memory units, continuing care retirement community, and skilled nursing facilities’ knowledge base through continuing medical education (CME) accredited in-service training.

Our core mission of enhancing the quality of life for patients by easing suffering and actively promoting safety, functionality, and dignity will never change,” said Dr. Posar. “We are also committed to providing our independent living, assisted living, memory unit, continuing care retirement community, and skilled nursing facility partners with the regulatory guidance and clinical protocols that we believe will enable them to increase their overall CMS star rating moving forward.”

For more information visit www.guidestareldercare.com or call 888-837-5440.

Contacts

Idalis Serna, The Motion Agency

312-565-0044 ext. 1154

Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran

Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran




Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran

– At 9 Months, Vutrisiran Met Primary and All Secondary Endpoints, with Statistically Significant Improvements in Neuropathy, Quality of Life (QoL), and Gait Speed, Relative to Placebo –

– In Majority of Patients, Vutrisiran Showed Reversal of Polyneuropathy Manifestations with Improvements in Neuropathy and QoL, Relative to Baseline –

– Vutrisiran Also Met Key Exploratory Endpoints Including Measures of Nutritional Status, Overall Disability, and Cardiac Biomarker (NT-proBNP), Relative to Placebo –

– Vutrisiran Demonstrated Encouraging Safety and Tolerability Profile –

– In Addition, Alnylam Submits New Drug Application (NDA) with U.S. Food and Drug Administration (FDA) for Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR (hATTR) Amyloidosis in Adults –

– Company to Host Conference Call Today at 4:00 pm ET –

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced full positive results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis, which met its primary and both secondary endpoints at nine months in patients with hereditary ATTR (hATTR) amyloidosis with polyneuropathy. The results were presented today in an oral session at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting.

The 9-month results achieved the study’s primary endpoint, with vutrisiran showing improvement in the mean change from baseline in the modified Neuropathy Impairment Score (mNIS+7) as compared to external placebo data from the APOLLO Phase 3 study of patisiran. At 9 months vutrisiran also met all secondary endpoints, demonstrating improvement in quality of life as assessed by the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN) instrument and improvement in gait speed as assessed by the timed 10-meter walk test (10-MWT), both compared to the external placebo group. The majority of patients experienced improvement in neuropathy and in quality of life, both relative to baseline, showing the potential for vutrisiran to reverse polyneuropathy manifestations of hATTR amyloidosis. Vutrisiran also demonstrated an encouraging safety profile with no drug-related discontinuations or deaths. Based on these positive data, Alnylam has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the approval of vutrisiran for the treatment of the polyneuropathy of hATTR amyloidosis in adults.

“The HELIOS-A study results demonstrate that vutrisiran improves neuropathy, quality of life and gait speed as soon as 9 months – compared to the external placebo arm of APOLLO – in patients with hATTR amyloidosis with polyneuropathy, with an encouraging safety and tolerability profile. The reversal of polyneuropathy manifestations of disease demonstrated in patients treated with vutrisiran in the study, the encouraging safety profile, and the totality of data from the trial, reinforce our belief in the promise of our RNAi therapeutics’ mechanism of action, as first established with ONPATTRO® (patisiran). Further, we are encouraged by the exploratory endpoint results showing the impact of vutrisiran on NT-proBNP, a marker of cardiac stress, and look forward to additional data on exploratory cardiac endpoints at the 18-month readout, expected in late 2021,” said Akshay Vaishnaw, M.D., Ph.D., President of R&D at Alnylam. “With our NDA filing now completed, we look forward to potentially bringing vutrisiran to patients as a new treatment option for the polyneuropathy of hATTR amyloidosis with subcutaneous administration and quarterly dosing. The positive HELIOS-A study and our NDA filing are key milestones as we continue our progress towards building an industry-leading franchise of medicines for the treatment of ATTR amyloidosis and towards our goal of expanding in the future the population of patients who may benefit from treatment with an RNAi therapeutic.”

HELIOS-A Study Results

At 9 months, vutrisiran met the primary and all secondary endpoints in HELIOS-A, specifically:

  • Vutrisiran achieved a rapid and sustained reduction in serum TTR levels with an 83 percent mean steady-state serum TTR reduction from baseline.

    • Consistent results in serum TTR level reduction were observed between the vutrisiran and patisiran arms of HELIOS-A, aligned with the therapeutic hypothesis.
  • Vutrisiran treatment (N=122) resulted in a 2.24 point mean decrease (improvement) in mNIS+7 score from baseline at 9 months as compared to a 14.76 point mean increase (worsening) reported for the external placebo group (N=77), resulting in a 17.0 point mean difference relative to placebo (p equal to 3.54×10-12).

    • Improvement in mNIS+7 from vutrisiran treatment was also consistently observed across all pre-specified patient subgroups, including age, sex, race, geographic region, baseline neuropathy impairment, genotype, prior TTR stabilizer use, baseline Familial Amyloid Polyneuropathy (FAP) stage, and inclusion in the pre-specified cardiac subpopulation.
    • Patients randomized to the patisiran reference arm in HELIOS-A showed results consistent with the vutrisiran arm.
  • Vutrisiran treatment resulted in a 3.3 point mean decrease (improvement) in Norfolk QoL-DN score from baseline at 9 months as compared to a 12.9 point mean increase (worsening) reported for the external placebo group, resulting in a mean 16.2 point difference relative to placebo (p equal to 5.43×10-9).
  • Patients treated with vutrisiran remained stable in gait speed (mean decrease of 0.001 meters/second in 10-MWT), while patients in the external placebo group demonstrated worsening (mean decrease of 0.133 meters/second in 10-MWT) (p equal to 3.10×10-5).
  • Improvement in the exploratory cardiac endpoint, NT-proBNP, a measure of cardiac stress, was observed in the vutrisiran arm in both the pre-specified cardiac sub-population and the modified intent-to-treat (mITT) population, relative to the external placebo group.

    • The cardiac subpopulation was defined as patients who had pre-existing evidence of cardiac amyloid involvement (baseline left ventricular wall thickness ≥1.3 cm and no aortic valve disease or hypertension in medical history). NT-proBNP adjusted geometric fold change from baseline was 0.95 for the vutrisiran cardiac subpopulation group (N=35) and 1.60 for the external placebo cardiac subpopulation (N=34) group, with an adjusted geometric fold change ratio of 0.60 (p equal to 0.0016) in favor of vutrisiran.
    • Similar results from baseline were seen in the mITT population in favor of vutrisiran relative to the external placebo group (p equal to 9.20×10-7).
  • In addition, vutrisiran demonstrated improvements in other exploratory endpoints measured at 9 months, including change from baseline in modified body mass index (mBMI) and the Rasch-built overall disability scale (R-ODS), relative to external placebo.

In the study and as previously reported with topline results from the HELIOS-A study, vutrisiran demonstrated an encouraging safety and tolerability profile relative to placebo with 9 months of dosing and there were no drug-related discontinuations or deaths. There were two study discontinuations (1.6 percent) due to adverse events in the vutrisiran arm by Month 9, both due to death, neither of which was considered related to study drug. There were two serious adverse events (SAEs) considered related to vutrisiran by the study investigator, consisting of dyslipidemia and urinary tract infection. Treatment emergent adverse events (AEs) occurring in 10 percent or more patients included diarrhea, pain in extremity, fall, and urinary tract infections, with each of these events occurring at a similar or lower rate as compared with external placebo arm. Injection site reactions (ISRs) were reported in five patients (4.1 percent) and were all mild and transient. There were no safety signals regarding hematology, renal function or liver function tests (LFTs).

“The results of the HELIOS-A Phase 3 study underscore the potential of vutrisiran as an attractive new treatment option that can be administered subcutaneously once every three months, considerably simplifying the treatment for patients with hATTR amyloidosis with polyneuropathy, a progressive, life-threatening, multi-system disease,” said David Adams, M.D., Ph.D., Department of Neurology, Bicetre hospital, Greater Paris University Hospitals, AP-HP, University Paris Saclay and Principal Investigator for the HELIOS-A trial. “The data released today are encouraging for the amyloidosis community who suffer from this devastating disease as we continue to see exciting progress from ongoing research focused on meeting the needs of this diverse group of patients.”

Regulatory Submissions

Alnylam also announced that it has submitted an NDA to the U.S. FDA for the approval of vutrisiran for the treatment of the polyneuropathy of hATTR amyloidosis in adults. Vutrisiran has been granted Orphan Drug Designation in the U.S. and the European Union (EU) for the treatment of ATTR amyloidosis. Vutrisiran has also been granted a Fast-Track designation in the U.S. for the treatment of the polyneuropathy of hATTR amyloidosis in adults. The Company plans to follow the FDA submission with regulatory filings in Brazil and Japan. The Company also plans to submit a Marketing Authorisation Application (MAA) in the EU upon obtaining the results of the 18-month analysis from the HELIOS-A Phase 3 Study, as previously aligned with the European Medicines Agency (EMA).

Conference Call

Alnylam management will discuss the full 9-month results from the HELIOS-A Phase 3 clinical trial via conference call on Monday, April 19th at 4:00 pm ET. A webcast presentation will also be available on the Investors page of the Company’s website, www.alnylam.com. To access the call, please dial 877-312-7507 (domestic) or +1-631-813-4828 (international) five minutes prior to the start time and refer to conference ID 9580096. A replay of the call will be available beginning at 7:00 pm ET on the day of the call. To access the replay, please dial 855-859-2056 (domestic) or +1-404-537-3406 (international) and refer to conference ID 9580096.

About Vutrisiran

Vutrisiran is an investigational, subcutaneously administered RNAi therapeutic in development for the treatment of ATTR amyloidosis, which encompasses both hereditary (hATTR) and wild-type (wtATTR) amyloidosis. It is designed to target and silence specific messenger RNA, blocking the production of wild-type and variant transthyretin (TTR) protein before it is made. Quarterly administration of vutrisiran may help to reduce deposition and facilitate the clearance of TTR amyloid deposits in tissues and potentially restore function to these tissues. Vutrisiran utilizes Alnylam’s Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate delivery platform, designed for increased potency and high metabolic stability that allows for infrequent subcutaneous injections. The safety and efficacy of vutrisiran have not been evaluated by the U.S. Food and Drug Administration, European Medicines Agency or any other health authority.

About HELIOS-A Phase 3 Study

HELIOS-A (NCT03759379) is a Phase 3 global, randomized, open-label study to evaluate the efficacy and safety of vutrisiran. The study enrolled 164 patients with hATTR amyloidosis with polyneuropathy at 57 sites in 22 countries. Patients were randomized 3:1 to receive either 25mg of vutrisiran (N=122) via subcutaneous injection once every three months or 0.3 mg/kg of patisiran (N=42) via intravenous infusion once every three weeks (as a reference comparator) for 18 months. The primary endpoint is the change from baseline in mNIS+7 score at 9 months, relative to an external placebo group (APOLLO). Secondary endpoints at 9 months are the change from baseline in the Norfolk QoL-DN score and the timed 10-MWT, relative to an external placebo group. Changes from baseline in NT-proBNP were evaluated as an exploratory endpoint at 9 months. The efficacy results of vutrisiran in HELIOS-A are compared to the placebo group from the landmark APOLLO Phase 3 study, which evaluated the efficacy and safety of patisiran in a patient population similar to that studied in HELIOS-A. Additional secondary endpoints at 18 months will be evaluated in the HELIOS-A study, including change from baseline in mNIS+7, Norfolk QoL-DN, 10-MWT, modified body mass index (mBMI), Rasch-built Overall Disability Scale (R-ODS), and serum transthyretin (TTR) levels. Additional exploratory cardiac endpoint data at the 18-month time point will be evaluated, including NT-proBNP, echocardiographic measures and cardiac amyloid assessments with technetium scintigraphy imaging. Following the 18-month study period, all patients are eligible to receive vutrisiran for an additional 18 months as part of an open-label extension study.

About hATTR Amyloidosis

Hereditary transthyretin (TTR)-mediated amyloidosis (hATTR) is an inherited, progressively debilitating, and fatal disease caused by variants (i.e., mutations) in the TTR gene. TTR protein is primarily produced in the liver and is normally a carrier of vitamin A. Variants in the TTR gene cause abnormal amyloid proteins to accumulate and damage body organs and tissue, such as the peripheral nerves and heart, resulting in intractable peripheral sensory-motor neuropathy, autonomic neuropathy, and/or cardiomyopathy, as well as other disease manifestations. hATTR amyloidosis, represents a major unmet medical need with significant morbidity and mortality affecting approximately 50,000 people worldwide. The median survival is 4.7 years following diagnosis, with a reduced survival (3.4 years) for patients presenting with cardiomyopathy.

About RNAi

RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines, known as RNAi therapeutics, is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran) being developed and commercialized by Alnylam’s partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.

Alnylam Forward Looking Statements

Various statements in this release concerning Alnylam’s expectations, plans, aspirations, and goals, including those related to vutrisiran and its potential as a low-dose, once quarterly, subcutaneously administered treatment option with an encouraging safety profile for patients with hATTR amyloidosis with polyneuropathy, encouraging exploratory cardiac endpoint results, the expected timing of regulatory filings for vutrisiran outside the U.S., building an industry-leading franchise in medicines for the treatment of ATTR amyloidosis and further growing the population of hATTR amyloidosis patients with polyneuropathy who may potentially benefit from treatment with an RNAi therapeutic, becoming a leading biotech company, and the achievement of its “Alnylam P5x25” strategy, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation: the direct or indirect impact of the COVID-19 global pandemic or any future pandemic on Alnylam’s business, results of operations and financial condition and the effectiveness or timeliness of Alnylam’s efforts to mitigate the impact of the pandemic; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for its product candidates; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; successfully launching, marketing and selling its approved products globally; delays, interruptions or failures in the manufacture and supply of its product candidates or its marketed products; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to successfully expand the indication for ONPATTRO in the future; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile in the future without the need for future equity financing; Alnylam’s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products, including Novartis, Regeneron and Vir; the outcome of litigation; the risk of government investigations; and unexpected expenditures; as well as those risks more fully discussed in the “Risk Factors” filed with Alnylam’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) and in its other SEC filings. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

This release is not intended to convey conclusions about efficacy or safety as to any investigational RNAi therapeutics or investigational uses of previously approved therapeutics. There is no guarantee that any investigational therapeutics or expanded uses of commercial products will successfully complete clinical development or gain health authority approval.

Contacts

Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
617-682-4340

Josh Brodsky

(Investors)

617-551-8276

Global Non-opioid Pain Patch Markets, 2021-2027: Market to Reach $4.7 Billion – Lidocaine Patches to Account for $1.3 Billion – ResearchAndMarkets.com

Global Non-opioid Pain Patch Markets, 2021-2027: Market to Reach $4.7 Billion – Lidocaine Patches to Account for $1.3 Billion – ResearchAndMarkets.com




Global Non-opioid Pain Patch Markets, 2021-2027: Market to Reach $4.7 Billion – Lidocaine Patches to Account for $1.3 Billion – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Non-opioid Pain Patch – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.

Global Non-opioid Pain Patch Market to Reach $4.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Non-opioid Pain Patch estimated at US$4.1 Billion in the year 2020, is projected to reach a revised size of US$4.7 Billion by 2027, growing at a CAGR of 2% over the analysis period 2020-2027.

Lidocaine Patches, one of the segments analyzed in the report, is projected to record a 2.3% CAGR and reach US$1.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Diclofenac Patches segment is readjusted to a revised 1.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 3.9% CAGR

The Non-opioid Pain Patch market in the U.S. is estimated at US$1.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$913 Million by the year 2027 trailing a CAGR of 3.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 0.3% and 1.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 0.8% CAGR.

Methyl Salicylate Patches Segment to Record 2.4% CAGR

In the global Methyl Salicylate Patches segment, USA, Canada, Japan, China and Europe will drive the 2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$462.8 Million in the year 2020 will reach a projected size of US$531.7 Million by the close of the analysis period.

China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$629.6 Million by the year 2027, while Latin America will expand at a 3.2% CAGR through the analysis period.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS (Total 42 Featured):

  • Acorda Therapeutics, Inc.
  • Allergan PLC
  • Endo Pharmaceuticals, Inc.
  • GlaxoSmithKline PLC
  • Hisamitsu Pharmaceutical Co., Inc.
  • IBSA Institut Biochimique SA
  • Mylan NV
  • Pfizer, Inc.
  • TEH SENG Pharmaceutical Mfg. Co., Ltd.
  • Teikoku Seiyaku Co. Ltd.

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

  • United States
  • Canada
  • Japan
  • China
  • Europe
  • France
  • Germany
  • Italy
  • United Kingdom
  • Spain
  • Russia
  • Rest Of Europe
  • Asia-Pacific
  • Australia
  • India
  • South Korea
  • Rest Of Asia-Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest Of Latin America
  • Middle East
  • Iran
  • Israel
  • Saudi Arabia
  • United Arab Emirates
  • Rest Of Middle East
  • Africa

IV. COMPETITION

  • Total Companies Profiled: 42

For more information about this report visit https://www.researchandmarkets.com/r/g7g08

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

South and Central America Addictions Therapeutics Market Report 2020-2027: Rising Demand for R&D from Contract Organizations – Leading Players are Indivior, Pfizer and GlaxoSmithKline – ResearchAndMarkets.com

South and Central America Addictions Therapeutics Market Report 2020-2027: Rising Demand for R&D from Contract Organizations – Leading Players are Indivior, Pfizer and GlaxoSmithKline – ResearchAndMarkets.com




South and Central America Addictions Therapeutics Market Report 2020-2027: Rising Demand for R&D from Contract Organizations – Leading Players are Indivior, Pfizer and GlaxoSmithKline – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “South and Central America Addictions Therapeutics Market Forecast to 2027 – COVID-19 Impact and Regional Analysis by Treatment Type; Drug Type; Treatment Center; Distribution Channel and Country” report has been added to ResearchAndMarkets.com’s offering.

Nicotine addiction treatment segment by type is estimated to lead the market

South and Central America Addictions Therapeutics Market is expected to reach US$ 482.04 million in 2027 from US$ 332.54 million in 2019. The market is estimated to grow with a CAGR of 4.9% from 2020 to 2027

By Inter-American Drug Abuse Control Commission (CICAD), the per capita consumption is estimated to be 30% higher than the global average in Latin America. The Addiction Centre report also stated that the number of people undertaking treatments for these addictions has increased in the recent years.

Thus, the rising awareness among people about drug addiction treatment is likely to support the growth of the South and Central America addiction therapeutics market in the coming years. Similarly, awareness campaigns and government efforts to counteract drug abuse and promote medication for all sorts of addiction treatments would fuel the market growth during the forecast period.

The growth of the market is attributed to rising approval of new drugs and launch of digital therapeutics to treat addiction, conduction of various awareness campaigns and government efforts to counteract drug abuse and promote medication. However, high costs associated with drug development is hindering the growth of the addiction therapeutics market.

Indivior PLC, Pfizer Inc. and GlaxoSmithKline plc are among the leading companies operating in the South and Central America addictions therapeutics market.

Key Market Dynamics

Market Drivers

  • Rising Addiction Among General Populace
  • Conduction of Awareness Campaigns

Market Restraint

  • Steeping Costs of Drug Development

Market Opportunity

  • Rising Demand for R&D from Contract Organizations

Future Trend

  • Consistent Launch of Therapeutics

The report segments in South and Central America Addictions Therapeutics market as follows:

By Treatment Type

  • Opioid Addiction Treatment
  • Alcohol Addiction Treatment
  • Nicotine Addiction Treatment
  • Other Substance Addiction Treatment

By Drug Type

  • Buprenorphine
  • Naltrexone
  • Bupropion
  • Disulfiram
  • Nicotine Replacement Products
  • Varenicline
  • Others

By Treatment Center

  • Inpatient Treatment Center
  • Residential Treatment Center
  • Outpatient Treatment Center

By Distribution Channel

  • Hospital Pharmacies
  • Medical stores
  • Others

By Country

  • Brazil
  • Argentina
  • Rest of South and Central America

For more information about this report visit https://www.researchandmarkets.com/r/588lot.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Clinical Trial Conducted by MedinCell Confirms the Safety of Continuous Administration of Ivermectin

Clinical Trial Conducted by MedinCell Confirms the Safety of Continuous Administration of Ivermectin




Clinical Trial Conducted by MedinCell Confirms the Safety of Continuous Administration of Ivermectin

MONTPELLIER, France–(BUSINESS WIRE)–Clinical trial validates the safety of ivermectin taken daily in oral form, to simulate the continuous release of the active substance by a long-acting injection.

No side effects were observed with the three doses of ivermectin tested up to 100 µg / kg.

MedinCell develops several long-acting injectable formulations of ivermectin, the most advanced aims at preventing infection from Covid-19 and its mutants for several months.

Positive results of the safety study

“All our programs are developed in accordance with the highest ethical standards and on the basis of reliable scientific principles with a view to potential massive deployment. Proving the safety of ivermectin in regular daily administration over a long period was an essential step for our ivermectin programs, in particular mdc-TTG in Covid-19,” said Joël Richard, Chief Development Officer at MedinCell.

Access the complete press release

About MedinCell

MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 140 people representing over 25 different nationalities.

Contacts

MedinCell

David Heuzé
Head of Communication
david.heuze@medincell.com
+33 (0)6 83 25 21 86

NewCap

Louis-Victor Delouvrier / Mathilde Bohin
Investor relations
medincell@newcap.eu
+33 (0)1 44 71 98 53

NewCap

Nicolas Merigeau
Media relations
medincell@newcap.eu
+33 (0)1 44 71 94 98

Global Alpha-1 Antitrypsin Drugs Market Trajectory & Analytics Report 2021: Market to Reach $2 Billion by 2027 – U.S. Market is Estimated at $319.3 Million, While China is Forecast to Grow at 9% CAGR – ResearchAndMarkets.com

Global Alpha-1 Antitrypsin Drugs Market Trajectory & Analytics Report 2021: Market to Reach $2 Billion by 2027 – U.S. Market is Estimated at $319.3 Million, While China is Forecast to Grow at 9% CAGR – ResearchAndMarkets.com




Global Alpha-1 Antitrypsin Drugs Market Trajectory & Analytics Report 2021: Market to Reach $2 Billion by 2027 – U.S. Market is Estimated at $319.3 Million, While China is Forecast to Grow at 9% CAGR – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Alpha-1 Antitrypsin Drugs – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.

Global Alpha-1 Antitrypsin Drugs Market to Reach $2 Billion by 2027

Amid the COVID-19 crisis, the global market for Alpha-1 Antitrypsin Drugs estimated at US$1.1 Billion in the year 2020, is projected to reach a revised size of US$2 Billion by 2027, growing at a CAGR of 9.6% over the period 2020-2027.

The U.S. Market is Estimated at $319.3 Million, While China is Forecast to Grow at 9% CAGR

The Alpha-1 Antitrypsin Drugs market in the U.S. is estimated at US$319.3 Million in the year 2020. China, the world’s second largest economy, is forecast to reach a projected market size of US$354.1 Million by the year 2027 trailing a CAGR of 9% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.9% and 7.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

(Total 43 Featured):

  • Abeona Therapeutics
  • Alnylam Pharmaceuticals
  • Applied Genetic Technologies Corp
  • Arrowhead Research Corporation
  • Baxalta
  • Baxter
  • CSL Behring
  • Grifols
  • Kamada
  • Shire
  • Takeda Pharmaceutical Company Limited

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • World Current & Future Analysis for Alpha-1 Antitrypsin Drugs by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • World Historic Review for Alpha-1 Antitrypsin Drugs by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • World 15-Year Perspective for Alpha-1 Antitrypsin Drugs by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

IV. COMPETITION

  • Total Companies Profiled: 43

For more information about this report visit https://www.researchandmarkets.com/r/ydf33k

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

2021 Market Innovations and Growth Opportunities in Neurostimulation Devices, Point of Care (POC) Diagnostics, and Novel Implant Platforms – ResearchAndMarkets.com

2021 Market Innovations and Growth Opportunities in Neurostimulation Devices, Point of Care (POC) Diagnostics, and Novel Implant Platforms – ResearchAndMarkets.com




2021 Market Innovations and Growth Opportunities in Neurostimulation Devices, Point of Care (POC) Diagnostics, and Novel Implant Platforms – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “2021 Innovations and Growth Opportunities in Neurostimulation Devices, Point of Care (POC) Diagnostics, and Novel Implant Platforms” report has been added to ResearchAndMarkets.com’s offering.

The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) profiles a wide range of innovations from the advanced medical device and imaging industry. Innovations in surgical robots are discussed in this issue.

The innovations cover various neuromodulation technologies for the treatment of various neurological conditions such as post traumatic stress disorder or bipolar disorder. The issue also profiles various surgical technology innovations such a magnetic balloon anchoring technology, laparoscopic lens cleaner, minimally invasive neuroendoscope, and virtual reality platform for surgery training.

Range of innovations in point-of-care disease diagnostic and monitoring for sleep apnea, kidney reflux, chronic kidney disease, COVID-19 infection, epilepsy, and blood pressure are also covered. These innovations portray the diversity in their technology readiness levels, indicating an immediate or potential market impact. The growth opportunities for all these advanced medical device technologies are also covered in this issue.

The Advanced MedTech TOE analyzes and reports new and emerging technologies; advances in R&D, product development and regulatory matters specifically related to the areas of CT, MRI, NM, PET, ultrasound, X-ray, neurology, ophthalmology, respiratory/anesthesia, wound care and management, surgical tools and instrumentation, drug delivery, orthopedics, endoscopy, cardiology, and monitoring.

In addition, relevant developments in fusion technologies, functional imaging technology, interventional cardiology and image guided surgery and healthcare IT related areas such as PACS, medical information storage, and disaster recovery/business continuance will also be covered.

Companies Mentioned

  • Acurable
  • Aktiia SA
  • Asimov Robotics Pvt. Ltd.
  • Aurigen Medical
  • Bioserenity
  • Ceregate GmbH
  • Clearcam Inc.
  • Clearmind Biomedical
  • Corneat Vision
  • Creatsens Health S.L.
  • Electrocore Inc.
  • Endostart S.R.L
  • HD Medical Inc. CA
  • Kite Medical
  • Lark Technologies Inc.
  • Livonyx Inc.
  • Neuronetics Inc.
  • Neurovalens
  • Nirmidas Biotech
  • Organogenesis Holdings Inc.
  • Osso VR Inc.
  • Perkinelmer
  • Royal Philips
  • Scone Medical Solutions
  • Spark Biomedical Inc.
  • Vestibular First

For more information about this report visit https://www.researchandmarkets.com/r/n80du7

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Insights on the Periodontal Therapeutics Global Market to 2027 – Featuring 3M, Align Technology and Bausch Health Companies Among Others – ResearchAndMarkets.com

Insights on the Periodontal Therapeutics Global Market to 2027 – Featuring 3M, Align Technology and Bausch Health Companies Among Others – ResearchAndMarkets.com




Insights on the Periodontal Therapeutics Global Market to 2027 – Featuring 3M, Align Technology and Bausch Health Companies Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Periodontal Therapeutics – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.

Amid the COVID-19 crisis, the global market for Periodontal Therapeutics estimated at US$336.9 Million in the year 2020, is projected to reach a revised size of US$605.5 Million by 2027, growing at a CAGR of 8.7% over the period 2020-2027.

Systemic Antibiotics, one of the segments analyzed in the report, is projected to record 8.7% CAGR and reach US$471.1 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Local Antibiotics segment is readjusted to a revised 9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $91.1 Million, While China is Forecast to Grow at 11.8% CAGR

The Periodontal Therapeutics market in the U.S. is estimated at US$91.1 Million in the year 2020. China, the world’s second largest economy, is forecast to reach a projected market size of US$125.8 Million by the year 2027 trailing a CAGR of 11.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.9% and 7.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.8% CAGR.

Select Competitors (Total 38 Featured):

  • 3M ESPE
  • Align Technology, Inc.
  • Bausch Health Companies Inc.
  • DenMat Holdings LLC
  • DENTSPLY International, Inc.
  • Eli Lilly and Company
  • Fibrocell Science, Inc.
  • Glidewell Laboratories
  • Kaken Pharmaceutical Co., Ltd.
  • Mallinckrodt Pharmaceuticals
  • Nobel Biocare Holding AG
  • OraPharma
  • Purdue Pharma LP
  • Teva Pharmaceutical Industries Ltd.
  • TOLMAR Pharmaceuticals, Inc.
  • Ultradent Products, Inc.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

  • UNITED STATES
  • CANADA
  • JAPAN
  • CHINA
  • EUROPE
  • FRANCE
  • GERMANY
  • ITALY
  • UNITED KINGDOM
  • SPAIN
  • RUSSIA
  • REST OF EUROPE
  • ASIA-PACIFIC
  • AUSTRALIA
  • INDIA
  • SOUTH KOREA
  • REST OF ASIA-PACIFIC
  • LATIN AMERICA
  • ARGENTINA
  • BRAZIL
  • MEXICO
  • REST OF LATIN AMERICA
  • MIDDLE EAST
  • IRAN
  • ISRAEL
  • SAUDI ARABIA
  • UNITED ARAB EMIRATES
  • REST OF MIDDLE EAST
  • AFRICA

IV. COMPETITION

  • Total Companies Profiled: 38

For more information about this report visit https://www.researchandmarkets.com/r/lmnzy0

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commercialization

Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commercialization




Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commercialization

  • Previously led partnering transactions and strategic analyses for multiple companies, including Roche, Pfizer, and Novartis
  • Dr. Fischette will focus on out-licensing the Company’s lead drug candidate for recurring breast cancer, GP2, and building a clinical pipeline to complement GP2
  • Dr. Fischette has 25+ years of experience in research, clinical development, commercialization, and business development at Big Pharma, leveraging her Ph.D. in Biology and Physiology

STAFFORD, Texas–(BUSINESS WIRE)–Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the appointment of Christine Fischette, Ph.D., to Vice President of Business Development.

Dr. Fischette commented, “I am very excited to lead the effort in building an expanded pipeline for the Company. The release of our final 5 year safety data from our Phase IIb trial at the upcoming ASCO conference, combined with our previously released clinical outcome and immune response data at SABCS 2020 and AACR 2021, will give us a complete data package to present to Big Pharma for the out-licensing of GP2. The GP2 Phase IIb clinical data showed no breast cancer recurrences in HER2+ patients over 5 years and a peak immune response after 6 months of treatment. If the final safety data is positive, which we expect it to be, we will have a compelling product profile which compares favorably to commercialized breast cancer drugs as well as those currently under development. Breast cancer survivors seek safe and effective drugs to prevent metastatic breast cancer recurrence. GP2 may represent a paradigm shift in the way we treat recurring breast cancer. I look forward to developing a partnership with Big Pharma to help us maximize the potential of GP2.”

CEO Snehal Patel added, “We are thrilled that Dr. Fischette is joining the Company. While she was invaluable in advising the Company in the past through our engagement with Torreya Partners, her expanded role and responsibilities inside the Company will not only include exploring strategic partnerships with Big Pharma for GP2, but will also include adding additional products to our clinical pipeline. Both of these activities are high priorities for the Company. We also look forward to Dr. Fischette’s contributions to our management team as we seek to expand the GP2 market from HER 2+ breast cancer to triple negative breast cancer and other HER2 expressing cancers, where the market potential of GP2 may exceed $5 billion.”

Dr. Fischette has over 30 years of experience in strategic and operational roles within research, drug development, commercialization, business development, and general management in the BioPharma industry. She has advised companies on growth strategies, business development, licensing, and drug development. She has also consulted for investment banks, biotech companies, academic institutions, non-profits, and she was a faculty member for BIO’s Business Development Fundamentals Course offered annually by BIO. Previously, Dr. Fischette worked at Torreya Partners, Novartis, Pfizer, and Roche. She served as Head of Negotiation and Board Director for several therapeutic business units at Novartis. At Pfizer, she orchestrated the entire drug development/marketing process of a therapeutic from formulation selection to successful commercialization with net sales eventually reaching $350 million. She has authored over 50 publications in peer-reviewed publications, including Science while at Rockefeller University and other institutions. Dr. Fischette received a B.A. in Biology Education from Rutgers University and a Ph.D. in Physiology from Rutgers Biomedical Health Sciences, formerly known as the University of Medicine and Dentistry of New Jersey.

About Breast Cancer and HER2/neu Positivity

One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. HER2/neu (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial. For more information on Greenwich LifeSciences, please visit the Company’s website at www.greenwichlifesciences.com and follow the Company’s Twitter at https://twitter.com/GreenwichLS.

About GP2 Immunotherapy Immune Response

As previously reported, GP2 immunotherapy generated GP2-specific immune responses, leading to no metastatic breast cancer recurrence in the HER2/neu 3+ population in the Phase IIb clinical trial, thus supporting GP2’s mechanism of action. Statistically significant peak immunity was reached after 6 months of GP2 treatment, as measured in both the Dimer Binding Assay and the DTH skin test. HER2/neu 3+ population immune response was similar to the HER2/neu 1-2+ population immune response, suggesting the potential to treat the HER2/neu 1-2+ population (including triple negative breast cancer) with GP2 immunotherapy in combination with trastuzumab (Herceptin) based products and other clinically active agents. The broad based immune response suggests the potential for GP2 to treat other HER2/neu 1-3+ expressing cancers. For more information on GP2 immune response and clinical data, please visit the Company’s clinical trial tab at https://greenwichlifesciences.com/clinical-trials/#Phase-IIb-AACR.

Forward-Looking Statement Disclaimer

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the public offering filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.

Contacts

Company Contact
Snehal Patel

Investor Relations

(832) 819-3232

info@greenwichlifesciences.com

Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry

RedChip Companies Inc.

Office: 1-800-RED CHIP (733 2447)

Cell: (407) 491-4498

dave@redchip.com

China Genome-Based Drug Industry Report 2021: Historical Data (2010, 2015 and 2020) and Long-Term Forecasts (2021-2030) – ResearchAndMarkets.com

China Genome-Based Drug Industry Report 2021: Historical Data (2010, 2015 and 2020) and Long-Term Forecasts (2021-2030) – ResearchAndMarkets.com




China Genome-Based Drug Industry Report 2021: Historical Data (2010, 2015 and 2020) and Long-Term Forecasts (2021-2030) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Genome-Based Drug Industry Forecasts – China Focus” report has been added to ResearchAndMarkets.com’s offering.

This study focuses on China’s Genome-Based Drug industry forecasts. In the two past decades, the industry has been growing at a fast pace.

The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services.

The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades.

Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market.

Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is suffering from minimal innovation and investment in R&D and new product development. The sector’s economies of scale have yet to be achieved. Most domestic manufacturers lack the autonomic intellectual property and financial resources to develop their own brand name products.

This new study focuses on industry trends and forecasts with historical data (2010, 2015 and 2020) and long-term forecasts through 2025 and 2030 are presented.

Key Topics Covered:

I. INTRODUCTION

  • Report Scope and Methodology
  • Executive Summary

II. BUSINESS ENVIRONMENT

  • Economic Outlook
  • Key Economic Indicators
  • Industrial Output
  • Population and Labor
  • Foreign Investment
  • Foreign Trade
  • Financial and Tax Regulations
  • Banking System and Regulations
  • Foreign Exchange
  • Taxes, Tariff and Custom Duties

III. GENOME-BASED DRUG SALES VOLUMES AND FORECASTS

  • Overview
  • Genome-Based Drug Sales Volumes and Forecasts (Yuan)
  • Cytokines Drug
  • Peptide Hormones Drug
  • Thrombolytic Agents
  • Enzyme Drug
  • Soluble Recepter
  • Adhesion Molecule
  • Nucleic Acid Drug
  • Other Genome-Based Drug
  • Genome-Based Drug Imports and Exports
  • Pricing Trends

For more information about this report visit https://www.researchandmarkets.com/r/umjw0p

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900